by Peter Ciszewski | Jul 22, 2018
Heather A. Lau, MD, Director, Lysosomal Storage Disease Program at NYU Langone in New York City discusses how physicians need to consider rare diseases for some of their more challenging diagnositic cases. Rare diseases are problematic on many fronts: (1)...
by Peter Ciszewski | Jul 21, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Jessica Rousset, Chief Operating Officer of CURE Pharmaceutical, discusses her company. CURE is an integrated drug delivery and development company and has...
by Peter Ciszewski | Jul 20, 2018
The U.S. Food and Drug Administration (FDA) approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. This is the first drug in its class (IDH1 inhibitors)...
by Peter Ciszewski | Jul 20, 2018
Editor’s Note: This interview was conducted at #Bio2018. Please pardon the background noise. Chris Garabedian discusses the challenges of our health care system in supporting the many emerging and innovative therapies entering the market. Chris also...
by Peter Ciszewski | Jul 19, 2018
Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals discusses Right To Try, which is aimed at allowing terminally ill Americans to try medicines that have passed Phase 1 of the FDA approval process and remain in...
